| Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin … C Yoo, K Kim, JH Jeong, I Kim, MJ Kang, J Cheon, BW Kang, H Ryu, ... The Lancet Oncology 22 (11), 1560-1572, 2021 | 157 | 2021 |
| Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis J Kang, I Hwang, C Yoo, K Kim, JH Jeong, HM Chang, SS Lee, DH Park, ... Investigational new drugs 36, 732-741, 2018 | 118 | 2018 |
| Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients SH Seo, SE Kim, YK Kang, BY Ryoo, MH Ryu, JH Jeong, SS Kang, ... BMC cancer 16, 1-9, 2016 | 103 | 2016 |
| Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker H Chae, D Kim, C Yoo, K Kim, JH Jeong, HM Chang, SS Lee, DH Park, ... European Journal of Cancer 120, 31-39, 2019 | 73 | 2019 |
| Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response J Kang, JH Jeong, HS Hwang, SS Lee, DH Park, DW Oh, TJ Song, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2020 | 68 | 2020 |
| Stereotactic body radiation therapy for locally advanced pancreatic cancer J Jung, SM Yoon, J Park, DW Seo, SS Lee, MH Kim, SK Lee, DH Park, ... PLoS One 14 (4), e0214970, 2019 | 58 | 2019 |
| HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF JH Jeong, J Kim, YS Hong, D Kim, JE Kim, SY Kim, K Kim, YK Yoon, ... Clinical colorectal cancer 16 (3), e147-e152, 2017 | 51 | 2017 |
| Clinical outcomes of conversion surgery after neoadjuvant chemotherapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer: a single … C Yoo, SH Shin, K Kim, JH Jeong, HM Chang, JH Kang, SS Lee, DH Park, ... Cancers 11 (3), 278, 2019 | 44 | 2019 |
| Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy S Kang, SH Lee, HJ Lee, H Jeong, JH Jeong, JE Kim, JH Ahn, KH Jung, ... European Journal of Cancer 176, 30-40, 2022 | 40 | 2022 |
| Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis C Yoo, SS Lee, KB Song, JH Jeong, J Hyung, DH Park, TJ Song, DW Seo, ... British Journal of Cancer 123 (3), 362-368, 2020 | 33 | 2020 |
| Interleukin-1β stimulates matrix metalloproteinase-2 expression via a prostaglandin E2-dependent mechanism in human chondrocytes Y Choi, DJ Lee, HK Lim, JH Jeong, JK Sonn, SS Kang, SH Baek Experimental & molecular medicine 36 (3), 226-232, 2004 | 33 | 2004 |
| FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma C Yoo, I Hwang, TJ Song, SS Lee, JH Jeong, DH Park, DW Seo, SK Lee, ... Therapeutic advances in medical oncology 12, 1758835920953294, 2020 | 26 | 2020 |
| Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer C Yoo, B Han, HS Kim, K Kim, D Kim, JH Jeong, JL Lee, TW Kim, JH Kim, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2018 | 26 | 2018 |
| Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized … J Hyung, I Kim, K Kim, BY Ryoo, JH Jeong, MJ Kang, J Cheon, BW Kang, ... JAMA oncology 9 (5), 692-699, 2023 | 22 | 2023 |
| Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II/III breast cancer: the neo-PATH … HK Ahn, SH Sim, KJ Suh, MH Kim, JH Jeong, JY Kim, DW Lee, JH Ahn, ... JAMA oncology 8 (9), 1271-1277, 2022 | 22 | 2022 |
| Feasibility of HER2-targeted therapy in advanced biliary tract cancer: A prospective pilot study of trastuzumab biosimilar in combination with gemcitabine plus cisplatin H Jeong, JH Jeong, KP Kim, SS Lee, DW Oh, DH Park, TJ Song, Y Park, ... Cancers 13 (2), 161, 2021 | 22 | 2021 |
| Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin J Hyung, B Kim, C Yoo, K Kim, JH Jeong, HM Chang, BY Ryoo Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2019 | 20 | 2019 |
| Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival W Lee, M Oh, JS Kim, Y Park, JW Kwon, E Jun, KB Song, JH Lee, ... British Journal of Surgery 109 (1), 61-70, 2022 | 18 | 2022 |
| Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter … H Chae, H Jeong, J Cheon, HJ Chon, H Ryu, IH Kim, MJ Kang, JH Jeong, ... Therapeutic Advances in Medical Oncology 12, 1758835920923424, 2020 | 18 | 2020 |
| Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based … I Hwang, J Kang, HNN Ip, JH Jeong, K Kim, HM Chang, C Yoo, BY Ryoo Investigational New Drugs 37, 584-590, 2019 | 17 | 2019 |
